|
|
|
|
Trial | Studied trt | Control trt | patients | tags | ROB | Trial result | All cause death | Recurrent thromboembolic event |
---|
|
|
EINSTEIN CHOICE (10mg), 2017 NCT | rivaroxaban 10mg | aspirin | | | | - | | |
DURAC II, 1997 | VKA | control | | | | - | | |
WODIT DVT, 2001 | VKA | control | | | | - | | |
WODIT PE, 2003 | VKA | control | | | | - | | |
AUREC FVII, 2009 | VKA | control | | | | - | | |
DACUS (Siragusa), 2008 NCT | VKA | control | | | | - | | |
PROLONG (Palarati), 2006 NCT | VKA | control | | | | - | | |
Vitotec, 2009 | warfarin | control | | | | - | | |
ELATE, 2003 | warfarin | low intensity warfarin | | | Risk of bias | - | | |
AMPLIFY EXT 2.5mg, 2013 | apixaban 2.5mg | placebo | | | | - | | |
AMPLIFY EXT 5mg, 2013 | apixaban 5mg | placebo | | | | - | | |
WARFASA, 2012 | aspirin | placebo | | | | - | | |
ASPIRE, 2012 | aspirin | placebo | | | | - | | |
RESONATE, 2013 | dabigatran | placebo | | | | - | | |
Van Gogh, 2007 NCT | idraparinux | placebo | | | Low risk of bias | - | | |
PREVENT, 2003 | low-intensity warfarin | placebo | | | Low risk of bias | - | | |
EISNTEIN EXT, 2010 | rivaroxaban 20mg | placebo | | | | - | | |
PADIS-PE (Couturaud), 2015 NCT | VKA | placebo | | | Low risk of bias | - | | |
LAFIT, 1999 | warfarin | placebo | | | Low risk of bias | - | | |
Levine, 1995 | warfarin | placebo | | | | - | | |
THRIVE 3, 2003 | ximelagatran | placebo | | | | - | | |
REMEDY, 2013 | dabigatran | warfarin | | | | - | | |
EINSTEIN CHOICE (20mg), 2017 NCT | rivaroxaban 20mg | aspirin | | | | - | | |
Boccalon, 2000 | LMWH at home | UFH in hospital | | | | negative | | |
Chong, 2005 | LMWH at home | UFH in hospital | | | | suggesting | | |
Daskalopoulos, 2005 | LMWH at home | UFH in hospital | | | | negative | | |
Koopman, 1996 | LMWH at home | UFH in hospital | | | | negative | | |
Levine, 1996 | LMWH at home | UFH in hospital | | | | negative | | |
Ramacciotti, 2004 | LMWH at home | UFH in hospital | | | | negative | | |
Faivre et al , 1988 | Minoctoparine | unfractionated heparin | | | | negative | | |
|
AMPLIFY-EXT 2.5mg, 2012 NCT | apixaban 2.5mg | discontinuation | | | Low risk of bias | suggesting | | |
AMPLIFY-EXT 5mg, 2012 NCT | apixaban 5mg | discontinuation | | | Low risk of bias | suggesting | | |
Botticelli DVT, 2008 NCT | apixaban (without LMWH) | LMWH/VKA | | | Exploratory | - | | |
AMPLIFY, 2013 NCT | apixaban (without LMWH) | LMWH/VKA | | DOAC without heparin | Low risk of bias | suggesting | | |
|
WARFASA, 2012 NCT | aspirin | discontinuation | | | Low risk of bias | suggesting | | |
ASPIRE, 2012 | aspirin | discontinuation | | | | suggesting | | |
|
Kakkar, 2003 | Bemiparin | warfarin | | | Risk of bias | negative | | |
|
RE-MEDY, 2011 NCT | dabigatran | warfarin | | | Low risk of bias | suggesting | | |
RE-SONATE, 2011 NCT | dabigatran | discontinuation | | | Low risk of bias | suggesting | | |
RE-COVER, 2009 NCT | heparin/dabigatran | heparin/VKA | | heparin - DOAC | Low risk of bias | suggesting | | |
|
CLOT (Lee), 2003 | extended dalteparin | standard treatment | | | | suggesting | | |
Das, 1996 | Dalteparin | warfarin | | | Risk of bias | negative | | |
Lee, 2003 | Dalteparin | warfarin | | | Risk of bias | suggesting | | |
Holmström, 1992 | once daily dalteparin | twice daily dalteparin | | | | negative | | |
Partsch, 1996 | once daily dalteparin | twice daily dalteparin | | | | negative | | |
Bratt et al , 1985 | Dalteparin | unfractionated heparin | | | | negative | | |
Holm et al , 1986 | Dalteparin | unfractionated heparin | | | | negative | | |
Bratt et al, 1990 | Dalteparin | unfractionated heparin | | | | negative | | |
Lindmarker et al , 1993 | Dalteparin | unfractionated heparin | | | | negative | | |
|
Hokusai-VTE Cancer, 2017 NCT | edoxaban | dalteparin | patients with cancer | | Risk of bias | negative | | |
|
Veiga, 2000 | Enoxaparin | acenocoumarol | | | Risk of bias | negative | | |
González-Fajardo, 2008 | Enoxaparin | coumarin | | | Risk of bias | - | | |
Cesarone, 2003 | extended enoxaparin | standard treatment | | | | negative | | |
Deitcher, 2006 | extended enoxaparin | standard treatment | | | | negative | | |
Meyer, 2002 | extended enoxaparin | standard treatment | | | | negative | | |
Pini, 1994 | Enoxaparin | warfarin | | | Risk of bias | negative | | |
Gonzalez-Fajardo, 1999 | Enoxaparin | warfarin | | | Risk of bias | suggesting | | |
Meyer, 2002 | Enoxaparin | warfarin | | | Risk of bias | negative | | |
Deitcher, 2003 | Enoxaparin | warfarin | | | Risk of bias | negative | | |
Merli, 2001 | once daily enoxaparin | twice daily enoxaparin | | | Low risk of bias | negative | | |
Merli (once daily vs UFH), 2001 | once daily enoxaparin | UFH | | | Low risk of bias | negative | | |
Simonneau et al , 1993 | Enoxaparin | unfractionated heparin | | | | negative | | |
|
MATISSE, 2004 | fondaparinux | enoxaparin | | | Low risk of bias | negative | | |
MATISSE PE, 2003 | fondaparinux | heparin | | | Risk of bias | negative | | |
|
Ott importé, 1998 | heparin+warfarin | placebo | | | Low risk of bias | negative | | |
Krahenbuhl, 1979 | subcutaneous heparin | intravenous heparin | | | | - | | |
Bentley, 1980 | subcutaneous heparin | intravenous heparin | | | | suggesting | | |
Andersson, 1982 | subcutaneous heparin | intravenous heparin | | | | - | | |
Hull, 1986 | subcutaneous heparin | intravenous heparin | | | | negative | | |
Doyle, 1987 | subcutaneous heparin | intravenous heparin | | | | negative | | |
Walker, 1987 | subcutaneous heparin | intravenous heparin | | | | suggesting | | |
Lopaciuk | subcutaneous heparin | intravenous heparin | | | | negative | | |
Pini, 1990 | subcutaneous heparin | intravenous heparin | | | | negative | | |
Nielsen importé, 1994 | heparin+phenprocoumon | phenylbutazone | | | | - | | |
|
Van Gogh (subgroup), 2011 | idraparinux | standard treatment | patients with cancer | | Exploratory | negative | | |
VanGogh DVT, 2007 NCT | idraparinux (without heparin) | heparin/VKA | | | Exploratory | suggesting | | |
VanGogh PE, 2007 NCT | idraparinux (without heparin) | heparin/VKA | | | Risk of bias | negative | | |
|
Siegbahn, 1989 | once daily logiparin | twice daily logiparin | | | | negative | | |
|
Lopaciuk, 1999 | Nadroparin | acenocoumarol | | | Risk of bias | negative | | |
Lopez-Beret, 2001 | Nadroparin | acenocoumarol | | | Risk of bias | negative | | |
Lopez Beret, 2001 | extended nadroparin | standard treatment | | | | negative | | |
Charbonnier, 1998 | once daily nadroparin | twice daily nadroparin | | | Low risk of bias | negative | | |
Collaborative European Multicentre, 1991 | Nadroparin | unfractionated heparin | | | | negative | | |
Prandoni et al , 1992 | Nadroparin | unfractionated heparin | | | | suggesting | | |
Lopaciuk et al , 1992 | Nadroparin | unfractionated heparin | | | | negative | | |
|
SELECT D, 2018 | rivaroxaban | dalteparin | patients with cancer | | Risk of bias | suggesting | | |
EINSTEIN-extension, 2009 NCT | rivaroxaban | discontinuation | | | Low risk of bias | suggesting | | |
EINSTEIN (subgroup), 2014 | rivaroxaban | enoxaparin | patients with cancer | | | suggesting | | |
Einstein-DVT Dose-Ranging Study, 2008 | rivaroxaban (without LMWH) | LMWH/VKA | | | | - | | |
Einstein-DVT Evaluation, 2010 NCT | rivaroxaban (without LMWH) | LMWH/VKA | | DOAC without heparin | Low risk of bias | suggesting | | |
Einstein-PE Evaluation, 2012 NCT | rivaroxaban (without LMWH) | LMWH/VKA | | | Risk of bias | - | | |
|
VanGogh extension, 2007 NCT | idraparinux | discontinuation | | | | suggesting | | |
|
Romera, 2009 | Tinzaparin | acenocoumarol | | | Risk of bias | suggesting | | |
Hull, 2006 | extended tinzaparin | standard treatment | | | | negative | | |
Hull, 2002 | Tinzaparin | warfarin | | | Risk of bias | negative | | |
Hull et al , 1992 | Tinzaparin | unfractionated heparin | | | | suggesting | | |
|
Schulman, 1995 | 6 months | 1.5 months | | | | suggesting | | |
Pinede, 2001 | 3-6 months | 1.5-3 months | | | | negative | | |
Wells (subgroup), 2005 | tinzaparin | dalteparin | | | | negative | | |
Levine, 1995 | warfarin | discontinuation | | | Low risk of bias | suggesting | | |
LAFIT (Kearon), 1999 | warfarin | discontinuation | | | | suggesting | | |
Agnelli, 2001 | warfarin | discontinuation | | | | negative | | |
Agnelli, 2003 | warfarin | discontinuation | | | | negative | | |
PREVENT (Ridker), 2003 | warfarin | discontinuation | | | | suggesting | | |
ELAET (Kearon), 2004 | warfarin | discontinuation | | | Low risk of bias | negative | | |
DURAC (Schulman), 1997 | warfarin | discontinuation | | | | suggesting | | |
PROLONG (Palareti), 2006 NCT | warfarin | discontinuation | | | | suggesting | | |
|
THRIVE III, 2003 | ximelagatran | discontinuation | | | Low risk of bias | suggesting | | |
Schulman (subgroup), 2003 | ximelagatran | placebo | patients with cancer | | | - | | |
Fiessinger , 2005 | ximelagatran | LMWH/VKA | | | Low risk of bias | - | | |
THRIVE I, 2003 | ximelagatran (without LMWH) | LMWH/VKA | | | | - | | |
|
|
PREPIC, 1998 | caval filter | no filter | | | Low risk of bias | suggesting | | |
|
|
THRIVE III, 2003 | ximelagatran | discontinuation | | | Low risk of bias | suggesting | | |
|
|
EINSTEIN CHOICE (20mg), 2017 NCT | rivaroxaban 20mg | aspirin | | | | - | | |
|
AMPLIFY-EXT 2.5mg, 2012 NCT | apixaban 2.5mg | discontinuation | | | Low risk of bias | suggesting | | |
AMPLIFY-EXT 5mg, 2012 NCT | apixaban 5mg | discontinuation | | | Low risk of bias | suggesting | | |
Botticelli DVT, 2008 NCT | apixaban (without LMWH) | LMWH/VKA | | | Exploratory | - | | |
AMPLIFY, 2013 NCT | apixaban (without LMWH) | LMWH/VKA | | DOAC without heparin | Low risk of bias | suggesting | | |
|
RE-MEDY, 2011 NCT | dabigatran | warfarin | | | Low risk of bias | suggesting | | |
RE-SONATE, 2011 NCT | dabigatran | discontinuation | | | Low risk of bias | suggesting | | |
RE-COVER, 2009 NCT | heparin/dabigatran | heparin/VKA | | heparin - DOAC | Low risk of bias | suggesting | | |
RE-COVER II, 2011 NCT | heparin/dabigatran | heparin/VKA | | heparin - DOAC | Low risk of bias | suggesting | | |
|
Hokusai-VTE Cancer, 2017 NCT | edoxaban | dalteparin | patients with cancer | | Risk of bias | negative | | |
Edoxaban Hokusai VTE, 2013 NCT | heparin/edoxaban | heparin/VKA | | heparin - DOAC | Low risk of bias | suggesting | | |
|
Van Gogh (subgroup), 2011 | idraparinux | standard treatment | patients with cancer | | Exploratory | negative | | |
|
SELECT D, 2018 | rivaroxaban | dalteparin | patients with cancer | | Risk of bias | suggesting | | |
EINSTEIN-extension, 2009 NCT | rivaroxaban | discontinuation | | | Low risk of bias | suggesting | | |
EINSTEIN (subgroup), 2014 | rivaroxaban | enoxaparin | patients with cancer | | | suggesting | | |
Einstein-DVT Dose-Ranging Study, 2008 | rivaroxaban (without LMWH) | LMWH/VKA | | | | - | | |
Einstein-DVT Evaluation, 2010 NCT | rivaroxaban (without LMWH) | LMWH/VKA | | DOAC without heparin | Low risk of bias | suggesting | | |
Einstein-PE Evaluation, 2012 NCT | rivaroxaban (without LMWH) | LMWH/VKA | | | Risk of bias | - | | |
|
VanGogh extension, 2007 NCT | idraparinux | discontinuation | | | | suggesting | | |
|
THRIVE III, 2003 | ximelagatran | discontinuation | | | Low risk of bias | suggesting | | |
Schulman (subgroup), 2003 | ximelagatran | placebo | patients with cancer | | | - | | |
THRIVE I, 2003 | ximelagatran (without LMWH) | LMWH/VKA | | | | - | | |
|
|
Kakkar (arvin), 1969 | arvin | no fibrinolysis | | | | - | | |
|
Schweizer tPA, 1998 | tPA+heparin | no fibrinolysis | | | | negative | | |
|
Arneson, 1978 | streptokinase | no fibrinolysis | | | | negative | | |
Common, 1976 | streptokinase | no fibrinolysis | | | | negative | | |
Elsharawy, 2002 | streptokinase | no fibrinolysis | | | | negative | | |
Schulman, 1986 | streptokinase | no fibrinolysis | | | | negative | | |
Tsapogas, 1973 | streptokinase | no fibrinolysis | | | | negative | | |
Kakkar (streptokinase), 1969 | streptokinase | no fibrinolysis | | | | negative | | |
Schweizer (systemic SK), 2000 | streptokinase | no fibrinolysis | | | | - | | |
|